

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 311/80, 407/04, 409/04, A61K 31/35</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/57106</b> <b>(43) International Publication Date:</b> 11 November 1999 (11.11.99)
<b>(21) International Application Number:</b> PCT/US99/09701 <b>(22) International Filing Date:</b> 4 May 1999 (04.05.99)  <b>(30) Priority Data:</b> 60/084,008 4 May 1998 (04.05.98) US  <b>(71) Applicant:</b> THE UNIVERSITY OF CONNECTICUT [US/US]; 263 Farmington Avenue, Farmington, CT 06030 (US).  <b>(72) Inventors:</b> MAKRIYANNIS, Alexandros; 348G Foster Drive, Willimantic, CT 06226 (US). LU, Dai; 1 South Eagleville Road, No. 16, Storrs, CT 06268 (US). KHANOLKAR, Atmaram; 1 South Eagleville Road, No. 55, Storrs, CT 06268 (US). MENG, Zhaoxing; 10 Blue Grass Drive, Middletown, CT 06457 (US).  <b>(74) Agents:</b> CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		<b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> NOVEL ANALGESIC AND IMMUNOMODULATORY CANNABINOID  <b>(57) Abstract</b>  Disclosed are novel compounds represented by the following structural formula: R-X-Y; and physiologically acceptable salts thereof. R is a tricyclic core of a cannabinoid or substituted cannabinoid. X is a covalent bond, -CH <sub>2</sub> - or -CHR <sub>1</sub> -, wherein R <sub>1</sub> is a C1 to C3 substituted or unsubstituted alkyl group. Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system. Also disclosed is a method of stimulating a CB1 and/or CB2 receptor in a subject. The method comprises administering to the subject a therapeutically effective amount of R-X-Y.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NOVEL ANALGESIC AND IMMUNOMODULATORY CANNABINOIDS

## BACKGROUND OF THE INVENTION

$\Delta^8$ -Tetrahydrocannabinol, the psychoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to control nausea and appetite and to lower intraocular pressure (Mechoulam, *Cannabinoids as Therapeutic Agents*, CRC Press, Boca Raton, FL (1986), Fride and Mechoulam, *Eur. J. Pharmacol.* 231:313 (1993), Crawley et al., *Pharmacol. Biochem. Behav.* 46:967 (1993) and Smith et al., *J. Pharm. Exp. Therap.* 270:219 (1994)). Compounds which stimulate the CB2 receptor have been shown to suppress the immune system (Mechoulam, *Cannabinoids as Therapeutic Agents*, CRC Press, Boca Raton, FL (1986), Fride and Mechoulam, *Eur. J. Pharmacol.* 231:313 (1993), Crawley et al., *Pharmacol. Behav.* 46:967 (1993) and Smith et al., *J. Pharm. Exp. Therap.* 270:219 (1994)).


## SUMMARY OF THE INVENTION

Disclosed herein is the discovery that cannabinoids with a monocyclic, a fused bicyclic, a bridged bicyclic


or a bridged tricyclic side chain at the C-3 position show improved binding affinities for the CB1 and/or CB2 receptor compared with known cannabinoids, which typically have a linear side chain at the C-3 position.

5 For example, the cannabinoids AMG3 and AMG14 have a  $K_i$  for the CB1 receptor of less than 1.0 nM and AM731 and AM732 have a  $K_i$  for the CB2 receptor of less than 10.0 nM (Example 2). In contrast, the  $K_i$  of


10  $\Delta^8$ -tetrahydrocannabinol for the CB1 and CB2 receptors is only 45 nM and 14 nM, respectively. The structures of these compounds are shown below.




AMG3




AMG14



AM731



AM732



Delta-8-Tetrahydrocannabinol

Based on these results, novel cannabinoids with  
5 increased binding affinity for the CB1 and CB2 receptors  
are disclosed. Also disclosed are methods of  
stimulating a CB1 and/or CB2 receptor in a subject.

One embodiment of the present invention is a  
compound represented by Structural Formula (I):

10

R-X-Y; (I)

and physiologically acceptable salts thereof.

R is a tricyclic core of a cannabinoid or substituted cannabinoid.

X is covalent bond, -CH- or -CHR<sub>1</sub>-, wherein R<sub>1</sub> is a C1 to C3 substituted or unsubstituted alkyl group.

5 Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic  
10 ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.

Another embodiment of the present invention is a method of stimulating a CB1 and/or CB2 receptor in a subject. The method comprises administering to the  
15 subject a therapeutically effective amount of a compound represented by Structural Formula (I).

The novel compounds of the present invention can be used to stimulate the CB1 or CB2 receptors in a subject at lower doses and higher selectivity than other known  
20 CB1 or CB2 receptor agonists. Thus, they are expected to produce fewer side-effects than known CB1 or CB2 receptor agonists when used for treatment, for example, in treating glaucoma, treating autoimmune disease (e.g., lupus erythematosus, rheumatoid arthritis, psoriasis,  
25 multiple sclerosis and inflammatory bowel disease such as ulcerative colitis and Crohn's disease), preventing tissue rejection in organ transplant patients, controlling nausea in patients undergoing chemotherapy and enhancing appetite and controlling pain in  
30 individuals with AIDS Wasting Syndrome. In addition, some of these compounds are selective agonists for either the CB1 (e.g., AM411) or CB2 receptor (e.g., AM731 and AM732).

-5-

## BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1C shows the structure of a number of examples of novel compounds included in the present invention.

5        Figures 2A and 2B shows the structure of a number of novel cannabinoid side chains which can be found in the compounds of the present invention.

Figure 3 is a schematic showing a general procedure for the preparation of  $\Delta^8$ -tetrahydrocannabinol analogs and 2- and 4- substituted deoxy- $\Delta^8$ -tetrahydrocannabinols.


Figure 4 is a schematic of the synthesis of cannabinol analogs with noncyclic side chains.

Figures 5A-5B is a schematic showing the preparation of the rescorinol starting materials used in the syntheses shown in Figures 3 and 4.

## DETAILED DESCRIPTION OF THE INVENTION

Cannabinoids have a core tricyclic ring system in which a monohydroxylated phenyl ring and a six membered ring are each fused to a central pyran ring or to a central six-membered lactone ring (preferably to a pyran ring). In addition, cannabinoids are able to induce characteristic physiological effects in mammals, including euphoria, delirium, drowsiness, hallucinations, weakness and/or hyporeflexia. The tricyclic core ring system of many cannabinoids is shown in Structural Formula (II). Other cannabinoids have the tricyclic core shown in Structural Formula (II), modified to include one or more double bonds in Ring A, for example, a double bond between carbons 8 and 9, between carbons 9 and 10 or between carbons 9 and 11. Yet other cannabinoids have the core structures

described above, modified so that the methyl group bonded to carbon 11 has been replaced, for example, with a hydrogen, hydroxyl, hydroxymethyl, halogen (e.g., chloro, bromo, iodo and fluoro), methoxy, ethoxy, nitrile, nitro, halogenated methyl, halogenated ethyl, methoxymethyl, ethoxymethyl, nitromethyl, ethyl or  $-\text{CH}_2\text{CN}$  group. In other cannabinoids, the hydroxyl group at position 1 of the core structure is replaced with  $-\text{H}$ ,  $-\text{OCH}_3$ ,  $-\text{NH}_2$  or  $-\text{NHCH}_3$ . The term "cannabinoid", as it is used herein, also refers to other compounds which: 1) induce one or more of the physiological effects described above which are characteristic of the cannabinoids and 2) have core structures which are related to Structural Formula (II). Also shown in Structural Formula (II) is a numbering system for the atoms in the core tricyclic structure.



(II)

Cannabinoids also generally have a linear alkyl side chain at position C-3 of the cannabinoid core. In the cannabinoids of the present invention, the linear alkyl side chain is replaced with a heterocyclic ring, a



substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.


Suitable substituents for a cannabinoid include groups which do not significantly diminish the ability of a cannabinoid to activate a cannabinoid receptor.

Substitutions can occur at positions 2, 4, 6a-10a or at the three methyl groups. Substitutions at more than one position are possible. Substituents which do not significantly diminish the biological activity of cannabinoids are generally small, pharmacophoric groups.

Examples include -H, -OH, -OCH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, halogen (e.g., chloro, bromo, iodo and fluoro), -CN, azido, isocyanate, isothiocyanate, -NO<sub>2</sub>, -CH<sub>3</sub>, -C(halogen)<sub>3</sub>, -CH<sub>2</sub>OH, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>(halogen), -CH<sub>2</sub>CN, -CH<sub>2</sub>NO<sub>2</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>C(halogen)<sub>3</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>NHCH<sub>3</sub> or -CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>.

Suitable substituents can be identified by testing modified cannabinoids in the *in vitro* CB1 or CB2 assays described in Example 2. Cannabinoids with other substituents can be prepared by modification of the synthetic procedures described in Example 1, e.g., by replacing alcohol (A) in the synthesis shown in Figure 3 or by replacing the ester/ketone starting material in Figure 4 with suitably substituted analogs.

Preferably, the tricyclic cannabinoid core is represented by Structural Formula (III):



(III)


5 Ring A has from zero to three endocyclic double bonds. Examples include wherein Ring A is completely saturated, wherein Ring A has three double bonds and wherein Ring A has one endocyclic double bond which connects carbons 9 and 10 or 9 and 11. Preferably, Ring  
 10 A has one endocyclic double bond which connects carbons 8 and 9. As used herein, a double bond between two ring atoms is an "endocyclic" double bond.

Z is  $>\text{C}(\text{CH}_3)_2$  or  $-\text{C}=\text{O}$ . Z is preferably  $>\text{C}(\text{CH}_3)_2$ .

R<sub>2</sub> is -H, -OH, -OCH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, halogen (e.g.,  
 15 chloro, bromo, iodo and fluoro), -CN, -NO<sub>2</sub>, -CH<sub>3</sub>,  
 -C(halogen)<sub>3</sub>, -CH<sub>2</sub>OH, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>,  
 -CH<sub>2</sub>(halogen), -CH<sub>2</sub>CN, -CH<sub>2</sub>NO<sub>2</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>C(halogen)<sub>3</sub>,  
 -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>NHCH<sub>3</sub> or -CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>. Preferably, R<sub>2</sub> is -CH<sub>3</sub>  
 or -CH<sub>2</sub>OH.

When the tricyclic cannabinoid core is represented by Structural Formula (III), X and Y, taken together, are a C5-C7 carbocyclic ring, a substituted C5-C7 carbocyclic ring, a C5-C7 heterocyclic ring or a C5-C7 substituted heterocyclic ring.

Carbocyclic rings are non-aromatic rings which have only carbon as the ring atoms. Preferably, carbocyclic rings include from about five to about seven ring carbons and are substituted or unsubstituted. Examples include substituted and unsubstituted cyclopentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane and cycloheptene. A preferred example is a substituted cyclohexane shown below in Structural Formula (IV):





15

(IV)

$R_3$  is -H or -CH<sub>3</sub>.

$R_4$  and  $R_5$  are independently -H, a C1-C8 straight chained alkyl group or a C1-C8 substituted straight chained alkyl group. Preferably, at least one of  $R_4$  and  $R_5$  is -H.

Heterocyclic rings are non-aromatic rings with carbon and one or more heteroatoms such oxygen, nitrogen and/or sulfur as ring atoms. Preferably, heterocyclic rings contain from about five to about seven ring atoms and are substituted or unsubstituted. Preferred examples of heterocyclic rings are shown below in Structural Formulas (V) and (VI):



(V)

(VI)


Z' and Z'' are independently -S-, -O-, -S(O)- or -N(R<sub>7</sub>)-. Preferably, Z' and Z'' are each -O- or -S-.

5 R<sub>6</sub> is a C1 to about C12 straight chained alkyl or substituted alkyl group. Preferably, R<sub>6</sub> is a C4 to C10 alkyl group.

R<sub>7</sub> is -H or -CH<sub>3</sub>.

Other examples of heterocyclic rings include  
 10 substituted and unsubstituted 1,3-dioxane, 1,4-dioxane, 1,3-dithiane, 1,4-dithiane, diazetane, tetrahydrofuran, tetrahydrothiophene, morpholine, thiomorpholine, pyrrolidine, piperazine, piperidine and thiazolidine.

A fused bicyclic ring comprises two rings which  
 15 share two ring atoms. Examples include systems such as decalin and tetralin. A preferred example of a fused bicyclic ring system is represented by Structural Formula (VII):





20

(VII)

R<sub>8</sub> is -H or -CH<sub>3</sub>; and

R<sub>9</sub> is -H, a C1-C4 alkyl group or a C1-C4 substituted or unsubstituted alkyl group.

A "bridged bicyclic ring" has two rings in which more than two ring atoms are shared by the two rings. Optionally, a bicyclic ring can have one or more ring heteroatoms such as oxygen, sulfur or nitrogen. A  
 5 preferred bridged bicyclic ring is a substituted or unsubstituted 2.2.1 seven membered system also referred to as a "norbornyl group". Examples of norbornyl groups are represented by Structural Formula (VIII) and (IX);




10

(VIII)


(IX)

$R_{10}$ - $R_{12}$  are independently -H, C1-C3 alkyl group or C1-C3 substituted alkyl group. Preferably,  $R_{10}$ - $R_{12}$  are independently -H or -CH<sub>3</sub>.


Other examples of suitable bridged bicyclic  
 15 structures include a 3.2.1 eight-membered bicyclic structure, a 3.3.1 nine-membered bicyclic structure and a 2.2.2 eight-membered structure and a 3.3.2 nine-membered structure. The structures of a 3.2.1 eight-membered bicyclic system, a 3.3.1 nine-membered bicyclic  
 20 system, a 2.2.2 eight-membered bicyclic system and a 3.3.2 nine-membered bicyclic system are provided by Structural Formulas (X) - (XIII):




(X)



(XI)



(XII)



(XIII)

5



In one example, the bridged bicyclic structures represented by Structural Formulas (X)-(XIII) are substituted by one or more methyl groups.

The nomenclature for bridged bicyclic and tricyclic ring systems indicates the number of ring atoms between bridgeheads. A "bridgehead" is an atom shared by both rings. For example, bicyclo 2.2.1. heptane, shown in Structural Formula (VIII), has two (C-2 and C-3), two (C-5 and C-6) and one (C-7) carbons between the bridgeheads (C-1 and C-4). The numbering scheme for the ring atoms in 2.2.1 heptane is also shown in Structural Formula (VIII).

Bridged tricyclic ring systems comprise three rings, each of which shares two or more ring atoms with each of the other two rings. Optionally, a bridged tricyclic ring can have one or more heteroatoms such as oxygen, nitrogen or sulfur. A preferred example is a substituted or unsubstituted 1,1,1,1,1,1-tricyclic ten-

20



membered ring system, also referred to as an "adamantyl" group. Examples of adamantyl groups are represented by Structural Formula (XIV) - (XVII):



5

(XIV)

(XV)



(XVI)

(XVII)

$R_{13}$ ,  $R_{14}$ ,  $R_{15}$  and  $R_{16}$  are independently -H, a C1-C3  
10 alkyl group or a C1 to C3 substituted alkyl group.  
Preferably,  $R_{13}$  is -CH<sub>3</sub>.

$X_1$  and  $X_2$  independently are >N- or >CH-.  
Preferably,  $X_1$  and  $X_2$  are >CH-.

In another preferred embodiment, the novel  
15 cannabinoid analogs of the present invention are  
represented by Formula (III), modified so that the  
hydroxyl group attached to the phenyl ring is replaced  
with an -H and/or modified so that the side chain is

attached to position four of the tricyclic cannabinoid core.

Another example of suitable bridged tricyclic system is a substituted or unsubstituted 0,1,1,1,1,1-  
5 tricyclic nine-membered ring system.

Suitable substituents for a carbocyclic ring, a heterocyclic ring, a fused bicyclic ring, a bridged bicyclic ring and a bridged tricyclic ring are generally C1-C8 alkyl groups, substituted C1-C8 alkyl groups and  
10 small, pharmacophoric groups. Examples of small, pharmacophoric groups include, but are not limited to, -H, -OH, -OCH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, halogen (e.g., chloro, bromo, iodo and fluoro), -CN, azido, isocyanate, isothiocyanate, -NO<sub>2</sub>,  
15 -CH<sub>3</sub>, -C(halogen)<sub>3</sub>, -CH<sub>2</sub>OH, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>(halogen), -CH<sub>2</sub>CN, -CH<sub>2</sub>NO<sub>2</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>C(halogen)<sub>3</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>NHCH<sub>3</sub> or -CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>. Alkyl groups can be straight chained or branched. Suitable substituents for an alkyl group include small, pharmacophoric groups, as  
20 described above.

Specific examples of the compounds of the present invention are shown in Figures 1 and 2.

In the structural formulas depicted herein, the single or double bond by which a chemical group or  
25 moiety is connected to the remainder of the molecule or compound is indicated by the following symbol:



For example, the corresponding symbol in Structural Formula (VIII) indicates that the norbornyl group, which  
30 is represented in Structural Formula (I) by Y, is connected to R or X in Structural Formula (I) by a



single covalent bond with between carbon three of the norbornyl group and R or X.

A "therapeutically effective amount" is the quantity of compound which results in a desired  
5 therapeutic effect in a subject, e.g., immune system suppression, decreased nausea in patients undergoing chemotherapy, increased appetite and/or decreased pain in individuals with AIDS Wasting Syndrome or intraocular pressure in individuals with glaucoma. The specific  
10 dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the subject being treated. Typically, a "therapeutically effective  
15 amount" of the compound ranges from about 10 mg/day to about 1000 mg/day, preferably from about 50 mg/day to about 500 mg/day.

As used herein, a "subject" refers to a human. An "animal" refers to veterinary animals, such as dogs,  
20 cats, horses, and the like, and farm animals, such as cows, pigs, guinea pigs and the like.

The compounds of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g.,  
25 intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to capsular and tablet formulations (for oral and rectal  
30 administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration).

The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives. Suitable physiologically acceptable vehicles may include saline, sterile water, 5 Ringer's solution, and isotonic sodium chloride solutions.

The compounds of the present invention can be prepared by the syntheses shown in Figures 3-5. Specific conditions for reactions shown in Figures 3-5 10 are provided in Example 1.

Also included in the present invention are physiologically acceptable salts of the novel compounds disclosed herein. Salts of compounds containing a phenolic group or other acidic functional group can be 15 prepared by reacting with a suitable base, for example, a hydroxide base or amine base. Salts of acidic functional groups contain a counteranion such as sodium, potassium, ammonium and the like. Salts of compounds containing an amine or other basic group can 20 be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with quaternary ammonium group also contain a counteranion such as chloride, bromide, 25 iodide, acetate, perchlorate and the like.

The novel compounds of the present invention have utilities other than immunomodulation. For example, the disclosed cannabinoids can be used to screen for cells which express cannabinoid receptors (CB1 or CB2). The 30 cells are contacted with a radiolabelled cannabinoid, washed to remove unbound compound and then counted to assess retained radioactivity. Cells which retain radioactivity bind cannabinoids and are therefore likely to

express a cannabinoid receptor. Preferably, the cannabinoid is a CB1 or CB2 selective cannabinoid and therefore identifies cells which express the CB1 or CB2 receptor, respectively.

5       The disclosed cannabinoids can also be used to identify other compounds which bind to a cannabinoid receptor. For example, radiolabelled cannabinoids can be used in place of CP-55,940 in the CB1 or CB2 assay described in Example 1. Radiolabeled cannabinoids can  
10 be prepared by, for example, by reducing the ketones used in Method II of Figure 5 with a suitable radiolabeled reducing agent such a tritiated sodium borohydride and oxidizing back to the ketone with a suitable oxidizing agent such as pyridinium chloro  
15 chromate (PCC). Preferably, the cannabinoid is selective for the CB1 or CB2 receptor.

The invention is illustrated by the following examples which are not intended to be limiting in any way.

20

## EXEMPLIFICATION

Example 1 - Preparation of the compound of the present invention

## Resorcinol synthesis

(I). Resorcinols synthesized by method I in Figure 5  
25       A procedure for preparing resorcinols is described in Dominiani, et al., *J. Org. Chem.* 42:344 (1977). The crude resorcinols obtained by this method were purified by silica gel column chromatography eluted with a 2:1 mixture of petroleum ether and acetone.

(II). Resorcinols synthesized by method II

*Preparation of 5-Bromo-3,5-Dimethoxy Benzene.* 100 mmol of 3,5-dimethoxyaniline were mixed with 75 ml of 48% hydrobromic acid. 150 mmol of sodium nitrite powder were added portionally over 20 minutes with rigorous stirring. The reaction was monitored by iodine-starch test paper until the paper turned blue. The resulting diazonium salt solution was added to a pre-prepared boiling solution of 50 mmol copper (I) bromide in 7 ml of 48% hydrobromic acid. The addition was complete after 20 minutes. The reaction mixture was then heated for 30 minutes with rigorous stirring. Steam distillation of the reaction mixture provided a white solid product with a yield of 40%.

*Preparation of 1'-hydroxy-1-alkyl-3,5-dimethoxybenzene.* 1 mmol of 3,5-dimethoxyphenylmagnesium bromide was prepared in 8 ml of anhydrous THF according to procedures disclosed in Harvill and Herbst, *J. Org. Chem.*, 9:21 (1944), the entire teachings of which are incorporated herein by reference. A solution of 1.1 mmol of a suitable ketone in 2 ml of anhydrous THF was added dropwise to the Grignard reagent solution. The mixture was refluxed for 2 to 3 hours and then quenched with the addition of saturated ammonium chloride solution. After work up and purification by column chromatography, product was collected in a yield of 95%.

*Preparation of 1-alkyl-3,5-dimethoxybenzene.* This compound was synthesized through lithium ammonia reduction of 1'-hydroxy-1-alkyl-3,5-dimethoxybenzene by the method described in Gray et al., *J. Org. Chem.*, Vol.40:3151 (1975), the entire teachings of which are incorporated herein by reference.

Preparation of 5-alkyl-resorcinol. This resorcinol was perpetrated by demethylation of 1-alkyl-3,5-dimethoxybenzene through the method described in Dominiami, et al., *J. Org. Chem.* 42:344 (1977), the  
5 entire teachings of which are incorporated herein by reference.

(III) Resorcinols synthesized by method III in Figure 5

Preparation of 1-alkyl-3,5-dimethoxybenzene. A ethereal 10 mmol of 3,5-dimethoxybenzylmagnesium bromide  
10 was prepared in the usual manner with 40 ml of anhydrous ether according to procedures disclosed in Harvill and Herbst, *J. Org. Chem.*, 9:21 (1944). The solution of Grignard reagent was concentrated to 15 ml and transferred into an Ace pressure tube containing a 10 ml  
15 ethereal solution of 10 mmol of a suitable tertiary alkyl bromide. The mixture was sealed and heated in a 100°C oil bath with stirring for 30 minutes, as described in Osama, et al., *J. Org. Chem.*, 36:205 (1971), Ohno, et al., *J. Org. Chem.*, 53:729 (1988) and  
20 Love, et al., *J. Med. Chem.*, 16:1200 (1973), the entire teachings of which are incorporated herein by reference. The crude product was purified through column chromatography with a yield about 25%.

Preparation of 5-alkyl-resorcinol. This resorcinol  
25 was prepared by demethylation of 1-alkyl-3,5-dimethoxybenzene by methods described in Dominiami, et al., *J. Org. Chem.*, 42:344 (1977), the entire teachings of which are incorporated herein by reference.

(IV). Resorcinols synthesized by method IV in Figure 5

30 The procedure for the preparation of these resorcinols is the same as described in (III), except

that the Grignard reagent was prepared using tetrahydrofuran.

(V). Resorcinols synthesized by method V in Figure 5

A mixture of 100 mmol resorcinol and 100 mmol  
5 tertiary alcohol in 200 ml of 70% methanesulfonic acid  
was stirred at 0°C for 12 hours for the preparation of  
linear side chain resorcinols, and stirred for 3 to 4  
hours at room temperature for preparation of cyclic side  
chain resorcinols. The reaction was quenched by  
10 addition of an excess of water. The crude product was  
purified by column chromatography. The column was  
eluted with 2:1 mixture of petroleum ether and acetone.  
Yield was about 70%.

Synthesis of  $\Delta^8$ -Tetrahydrocannabinol Analogs Via the  
15 Method of Scheme 1 of Figure 3.

A mixture of 1 mmol of the resorcinol, 1 mmol  
trans-p-mentha-2, 8-dien-1-ol and 18 mg of p-  
toluenesulfonic acid monohydrate in 10 ml of chloroform  
was stirred and heated in a 70°C oil bath for 2 to 4  
20 hours. Then the reaction temperature was lowered to  
room temperature and quenched by addition of 5 ml of  
saturated sodium bicarbonate solution. After  
separation, the aqueous layer was extracted twice with  
methylene chloride. The combined organic layer was  
25 washed with brine and dried over sodium sulfate.  
Removal of solvent by vacuum evaporation provides a  
yellow oil crude product. The product was purified by  
column chromatography. By eluting with 20:1 mixture of  
petroleum ether and ethyl acetate. The yield was  
30 generally about 65%. For some stereoisomers, HPLC

purification was performed with a chiral column. The mobil phase was a mixture of hexane and isopropanol.

Synthesis of 1-Deoxy- $\Delta^8$ -Tetrahydrocannabinol Via the Method of Scheme 2 in Figure 3

- 5        A mixture of 1 mmol of the phenol, 3 mmol trans-p-mentha-2, 8-dien-1-ol and 35 mg of p-toluenesulfonic acid monohydrate in 10 ml of chloroform was stirred and heated in a 70°C oil bath for 4 to 8 hours. Then the reaction temperature was lowered to room temperature.
- 10      The reaction was quenched by addition of 5 ml of saturated sodium bicarbonate solution. After separation, the aqueous layer was extracted twice by methylene chloride. The combined organic layer was washed by brine and dried over sodium sulfate. Removal
- 15      of solvent by vacuum evaporation provided a yellow oil crude product. The product was purified by column chromatography, eluting with 20:1 mixture of petroleum ether and ethyl acetate. The yield was generally about 15% to 20%.

20      Synthesis of Cannabinol and 1-Deoxy-Cannabinol Analogs Via the Method of Scheme 3 of Figure 4

- The experimental procedures are as described in Love, et al., *J. Med. Chem.*, 16:1200 (1973), Meltzer, et al., *Synthesis*, 1981, 985, and Gareau, et al., *Bioorg. Med. Chem. Lett.*, 6:189 (1996), the entire teachings of
- 25      which are incorporated herein by reference.

Example 2 - Compounds of the present invention bind to the CB1 and/or CB2 receptor

#### RADIOLIGAND BINDING ASSAY

The binding affinities of the novel compounds described in this invention for the central cannabinoid receptor was assessed using rat forebrain membranes as a source of CB1. Membranes were prepared as described by the method of Dodd et al., *Brain Res.* 226:107 (1981), the entire teachings of which are incorporated herein by reference. Rat whole brains minus the cerebral cortex were diced with a razor blade and homogenized in 0.32 M sucrose, pH 7.4. The resulting suspension was spun at 400 x g at 4°C. The supernatant was decanted and layered over 1.2 M sucrose in TME buffer (25 mM Tris base, 5 mM MgCl<sub>2</sub>, 1 mM EDTA, pH 7.4) and spun at 109,000 x g. The interface containing plasma membrane protein was collected, pooled and layered over 0.8 M sucrose in TME, pH 7.4. The pellet was carefully resuspended in TME, pH 7.4 and the total protein content was assayed by the method of Markwell et al., *Anal. Biochem.* 87:206 (1978), the entire teachings of which are incorporated herein by reference. Protein was aliquotted, frozen under liquid nitrogen and stored at -80°C until use.

Approximately 30µg of tissue was incubated in silanized 96 well microtiter plate with TME containing 0.1% essentially fatty acid free bovine serum albumin (BSA), 0.8 nM [<sup>3</sup>H]CP-55,940 and various concentrations of the test compound in a final volume of 200 µL. Assays were incubated at 30°C for 1 hour. The samples were filtered using Packard Filtermate 196 and Whatman GF/C Filterplates and washed with wash buffer (TME)



containing 0.5% BSA. Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count.

- 5 Nonspecific binding was assessed using 100 nM CP-55,940. Data collected from three independent experiments performed with duplicate determinations were normalized between 100% and 0% specific binding for [ $H^3$ ]CP-55,940, determined using buffer and 100 nM CP-55,940. The
- 10 normalized data was analyzed using a 4 parameter nonlinear logistic equation to yield  $IC_{50}$  values. Data from at least two independent experiments performed in duplicate were used to calculate  $IC_{50}$  values which were converted to  $K_i$  values using the assumptions of Cheng and
- 15 Prusoff, *Biochem. Pharmacol.*, 22:3099 (1973), the entire teachings of which are incorporated herein by reference.

Mouse spleen was used a source of CB2 receptors to assess binding affinity of analogs described in this invention. The CB2 binding assay was conducted in the

20 same manner as for CB1. Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption.

The  $K_i$ s (nanomolar) for a number of the compounds of the present invention are shown in the Table below:

Table

Compound	K <sub>i</sub> in nM for the CB1 Receptor	K <sub>i</sub> in nM for the CB2 Receptor
AM405	19.1	
AM406	14.5	
5 AM410	25.8	22.3
AM409	75.3	
AM407	9.1	
AM408	18.3	
AM412	182.9	85.0
10 AMG3	0.32	1.7
AMG9	3.6	
AMG14	0.2	
AM411	6.9	52.0
AM722	78.2	40.3
15 AM729	29.3	26.9
AM723	382.6	2845.0
AM728	30.7	32.8
AM731	60.6	6.1
AM732	20.1	2.0


20        While this invention has been particularly shown  
and described with references to preferred embodiments  
thereof, it will be understood by those skilled in the  
art that various changes in form and details may be made  
therein without departing from the spirit and scope of  
25 the invention as defined by the appended claims.

## CLAIMS

What is claimed is:

1. A compound represented by the following structural formula:

5



and physiologically acceptable salts thereof,  
wherein:

R is a tricyclic core of a cannabinoid or  
substituted cannabinoid;

10


X is a covalent bond, -CH- or -CHR<sub>1</sub>-, wherein  
R<sub>1</sub> a C1 to C3 substituted or unsubstituted alkyl  
group; and

15

Y is a heterocyclic ring, a substituted  
heterocyclic ring, a carbocyclic ring, a  
substituted carbocyclic ring, a fused bicyclic ring  
system, a substituted fused bicyclic ring system, a  
bridged bicyclic ring system, a substituted bridged  
bicyclic ring system, a bridged tricyclic ring  
system or a substituted bridged tricyclic ring  
system.

20

2. The compound of Claim 1 wherein R is represented by  
the following structural formula:




wherein Ring A has zero to three endocyclic double bonds;


5           Z is  $>\text{C}(\text{CH}_3)_2$  or  $-\text{C}=\text{O}$ ; and

$\text{R}_2$  is  $-\text{H}$ ,  $-\text{OH}$ ,  $-\text{OCH}_3$ ,  $-\text{OCH}_2\text{CH}_3$ , halogen,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{CH}_3$ ,  $-\text{C}(\text{halogen})_3$ ,  $-\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{OCH}_3$ ,  $-\text{CH}_2\text{OCH}_2\text{CH}_3$ ,  $-\text{CH}_2(\text{halogen})$ ,  $-\text{CH}_2\text{CN}$ ,  $-\text{CH}_2\text{NO}_2$ ,  $-\text{CH}_2\text{CH}_3$  or  $-\text{CH}_2\text{C}(\text{halogen})_3$ ,  $-\text{CH}_2\text{NH}_2$ ,  $-\text{CH}_2\text{NHCH}_3$  or  $-\text{CH}_2\text{N}(\text{CH}_3)_2$ .

10

3. The compound of Claim 2 wherein R is represented by the following structural formula:






wherein  $R_2$  is  $-CH_3$  or  $-CH_2OH$ .

4. The compound of Claim 3 wherein the compound is represented by the following structural formula:

5

wherein X is a covalent bond and Y is a C5-C7 carbocyclic ring, a substituted C5-C7 carbocyclic ring, a C5-C7 heterocyclic ring or a C5-C7 substituted heterocyclic ring.

- 10 5. The compound of Claim 4 wherein X is represented by the following structural formula:



wherein:


$R_3$  is  $-H$  or  $-CH_3$ ;

15

$R_4$  and  $R_5$  are independently  $-H$  or a C1 to C8 substituted or unsubstituted straight chained alkyl group and wherein at least one of  $R_4$  and  $R_5$  is  $-H$ .

6. The compound of Claim 4 wherein X is a covalent bond and Y is represented by a structural formula selected from:

5



wherein:


Z' and Z'' are independently -S-, -O- or -N(R<sub>7</sub>)-;

10

R<sub>6</sub> is a substituted or unsubstituted C1 to about C12 straight chained alkyl group; and  
R<sub>7</sub> is -H or -CH<sub>3</sub>.

7. The compound of Claim 6 wherein Z' and Z'' are each -O- or -S- and R<sub>6</sub> is a C4 to C10 alkyl group.

- 15 8. The compound of Claim 4 wherein X is a covalent bond and Y is represented by the following structural formula:




20

wherein:

R<sub>8</sub> is -H or -CH<sub>3</sub>; and

$R_9$  is -H, a substituted or unsubstituted C1-C4 alkyl group.

9. The compound of Claim 3 wherein X is a covalent bond and Y is a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.
10. The compound of Claim 9 wherein Y is a substituted or unsubstituted 0,1,1,1,1,1-tricyclic nine-membered ring system, 1,3,3-bicyclic nine-membered ring system, 1,2,3-bicyclic eight-membered ring system, 1,1,1,1,1,1-tricyclic ten-membered ring system, 1,1,3-bicyclic nine-membered ring system or 1,3-bicyclic six-membered ring system.
11. The compound of Claim 3 wherein the X is a covalent bond and Y is a substituted or unsubstituted norbornyl ring system.
12. The compound of Claim 11 wherein the norbornyl ring system is represented by the following structural formula:




wherein  $R_{10}$ - $R_{12}$  are independently -H, C1-C3 alkyl group or C1-C3 substituted alkyl group.

13. The compound of Claim 12 wherein  $R_{10}$ - $R_{12}$  are independently -H or  $-\text{CH}_3$ .

14. The compound of Claim 3 wherein X is a covalent bond and Y is a substituted or unsubstituted  
5 adamantyl ring system which contains zero, one or two heteroatoms.

15. The compound of Claim 14 wherein Y is represented by the structural formula:

10



wherein:

$R_{13}$ ,  $R_{14}$ ,  $R_{15}$  and  $R_{16}$  are independently -H, C1-C3 alkyl group or C1 to C3 substituted alkyl group;  
and


15

$X_1$  and  $X_2$  independently are  $>\text{N}-$  or  $>\text{CH}-$ .



16. The compound of Claim 15 wherein  $R_{14}$ - $R_{16}$  are each -H,  $R_{13}$  is -CH<sub>3</sub> and  $X_1$  and  $X_2$  are >CH-.

17. A method of stimulating a CB1 or CB2 receptor in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:




and physiologically acceptable salts thereof;  
wherein:

10 R is a tricyclic core of a cannabinoid or substituted cannabinoid;

X is a covalent bond, -CH<sub>2</sub>- or -CHR<sub>1</sub>-, wherein  $R_1$  a C1 to C3 substituted or unsubstituted lower alkyl group; and

15 Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.

18. The method of Claim 17 wherein R is represented by the following structural formula:




wherein Ring A has zero to three endocyclic double bonds;

Z is  $>\text{C}(\text{CH}_3)_2$  or  $-\text{C}=\text{O}$ ; and

5         $\text{R}_2$  is  $-\text{H}$ ,  $-\text{OH}$ ,  $-\text{OCH}_3$ ,  $-\text{OCH}_2\text{CH}_3$ , halogen,  $-\text{CN}$ ,  
 $-\text{NO}_2$ ,  $-\text{CH}_3$ ,  $-\text{C}(\text{halogen})_3$ ,  $-\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{OCH}_3$ ,  
 $-\text{CH}_2\text{OCH}_2\text{CH}_3$ ,  $-\text{CH}_2(\text{halogen})$ ,  $-\text{CH}_2\text{CN}$ ,  $-\text{CH}_2\text{NO}_2$ ,  $-\text{CH}_2\text{CH}_3$ ,  
 $\text{CH}_2\text{NH}_2$ ,  $-\text{CH}_2\text{NHCH}_3$ ,  $-\text{CH}_2\text{N}(\text{CH}_3)_2$  or  $-\text{CH}_2\text{C}(\text{halogen})_3$ .

10    19. The method of Claim 17 wherein R is represented by  
the following structural formula:




wherein  $R_2$  is  $-CH_3$  or  $-CH_2OH$ .

20. The method of Claim 19 wherein X is a covalent bond  
and Y is a substituted or unsubstituted norbornyl  
ring system.

5

21. The method of Claim 20 wherein the norbornyl ring  
system is represented by the following structural  
formula:




10

wherein  $R_{10}$ - $R_{12}$  are independently  $-H$ , C1-C3  
alkyl or C1-C3 substituted alkyl.

22. The method of Claim 21 wherein  $R_{10}$ - $R_{12}$  are  
independently  $-H$  or  $-CH_3$ .

23. A substituted or unsubstituted cannabinoid having substituted at C-3 with a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring, a substituted fused bicyclic ring, a bridged bicyclic ring, a substituted bridged bicyclic ring, a bridged tricyclic ring or a substituted bridged tricyclic ring, and physiologically acceptable salts thereof.


1/9




R =




AM405




AM406




AM410



AM409




AM407




AM408

FIGURE 1A


2/9




AM412



AMG3




AMG9




AMG14


FIGURE 1B




AM411




AM722




AM729




AM723



AM728



AM731



AM732

FIGURE 1C




FIGURE 2A







FIGURE 2B

## SCHEME 1



## SCHEME 2.




FIGURE 3

Scheme 3.











FIGURE 4

**Method I:**

ROH is tertiary or secondary alcohols

R =

**Method II:****FIGURE 5A**

**Method III:****Method IV:****Method V:**

ROH is tertiary alcohol

**FIGURE 5B**

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/09701

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C07D311/80 C07D407/04 C07D409/04 A61K31/35

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 240 003 A (LILLY) 7 March 1975 (1975-03-07) page 8; claims	1, 5, 17, 23
X	T.MAVROMOUSTAKOS ET AL.: "STUDIES ON THE THERMOTROPIC EFFECTS OF CANNABINOIDS" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1281, no. 2, 1996, pages 235-244, XP002111823 AMSTERDAM page 235 - page 236; figure 5; examples AMG18,3	1, 6, 17, 23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 August 1999

Date of mailing of the international search report

24/08/1999

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/09701

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>K.E. FAHRENHOLTZ: "THE SYNTHESIS OF 2 METABOLITES OF - DELTA8 TETRAHYDROCANNABINOL" JOURNAL OF ORGANIC CHEMISTRY., vol. 37, no. 13, 1972, pages 2204-2207, XP002111824 AMERICAN CHEMICAL SOCIETY. EASTON., US ISSN: 0022-3263 page 2204 - page 2205; examples 6,13</p> <p style="text-align: center;">----</p>	1,2,6
X	<p>KEN MATSUMOTO ET AL.: "CANNABINOIDS" JOURNAL OF MEDICINAL CHEMISTRY., vol. 20, no. 1, 1977, pages 17-24, XP002111825 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 page 17 - page 22; tables II,III</p> <p style="text-align: center;">-----</p>	1,2,5, 17,23

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 99/ 09701

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 17-22  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/09701

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2240003 A	07-03-1975	US 3886184 A	27-05-1975
		AR 202030 A	09-05-1975
		AR 202509 A	13-06-1975
		AT 336608 B	10-05-1977
		AT 633274 A	15-09-1976
		AU 7105574 A	15-01-1976
		BE 818418 A	03-02-1975
		BG 22829 A	20-04-1977
		CA 1023754 A	03-01-1978
		CH 605893 A	13-10-1978
		DD 112999 A	12-05-1975
		DE 2437135 A	13-02-1975
		DK 413074 A	01-04-1975
		GB 1481222 A	27-07-1977
		IE 39555 B	08-11-1978
		JP 50041866 A	16-04-1975
		JP 60011037 B	22-03-1985
		NL 7410351 A	05-02-1975
		PH 10463 A	25-04-1977
		SE 7409999 A	04-02-1975
		ZA 7404095 A	25-02-1976

